How adaptations can make cancer treatment more difficult
A technique known as single cell sequencing enables researchers to study gene expression – the activity of individual genes – across thousands of cells at the same time. Tumors consists of subpopulations of cells which, in addition to having different characteristics, continually adapt to changes in their microenvironment. Using single cell sequencing, a team of researchers led by PD Dr. Markus Morkel and Prof. Dr. Nils Blüthgen from Charité’s Institute of Pathology studied the inherent heterogeneity of tumor tissues in order to gain a clearer picture of the colorectal cancer development process.
The researchers started by comparing colorectal cancer cells with cells found in healthy gut tissue. By collecting data on a total of more than 100,000 individual cells, they were able to define cell characteristics which were universal across individual patients. Conventional sequencing methods only provide a picture of gene activity at a specific moment in time. In order to recreate and observe the dynamic changes taking place in tissues at the cellular level, the researchers had to create three-dimensional cultures of colorectal cancer cells. “Using these ‘organoids’ as they are called, we were able to trace the cells’ developmental trajectory,” explains PD Dr. Morkel, adding: “Thanks to a clever laboratory technique, we were able to label the cells’ RNA at a specific point in time. In addition to determining the current status of activity for each individual cell, this technique also provided us with a picture of gene expression from a few hours earlier.” The research team then examined the way in which the cancer cells within these organoids adapted to clinically important therapies with targeted inhibitors. Not all of the cancer cells responded in the same way. While some cells were extinguished by this treatment, others took what might be best described as ‘a wrong turn’. Deviating from their normal developmental trajectories, they entered a new state which rendered them resistant to the recently administered treatments.
“These types of single cell experiments with cancer tissues represent a huge logistical and technical challenge. They involve collaborations between specialists across multiple facilities – ranging from surgical specialists to database experts,” explains PD Dr. Morkel, who also serves as the main point of contact at the BIH at Charité’s Bioportal Single Cells, a core facility which aims to enable the fast and efficient incorporation of single cell technologies in near-patient translational research. One obvious challenge is addressed by Prof. Blüthgen, who is also a researcher at the Integrative Research Institute (IRI) for the Life Sciences at the Humboldt-Universität zu Berlin (HU): “Measuring the activity of thousands of genes in hundreds of thousands of cells produces very large volumes of data,” he explains, adding: “It is mainly due to advances in the field of machine learning that we are now in a position to analyze these data in an efficient way. This enables us to gain a better understanding of the essential cellular processes and then use this for the benefit of patients.” Single cell experiments, machine learning and patient-specific cell culture models are set to play a key role in the research and development of new cancer treatment options at Charité.
To see the original report from the Charité Berlin, please click here.
Original publication: Florian Uhlitz, Philip Bischoff, Stefan Peidl, Anja Sieber, Alexandra Trinks, Mareen Lüthen, Benedikt Obermayer, Eric Blanc, Yana Ruchiy, Thomas Sell, Soulafa Mamlouk, Roberto Arsie, Tzu-Ting Wei, Kathleen Klotz-Noack, Roland F Schwarz, Birgit Sawitzki, Carsten Kamphues, Dieter Beule, Markus Landthaler, Christine Sers, David Horst, Nils Blüthgen, Markus Morkel: Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer, https://doi.org/10.15252/emmm.202114123